AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14709244 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV) 400 mg bid plus interferon alpha‐2b (IFN‐alpha) 5 mU daily for the first 6 weeks, followed by 3 mU tiw until completing 6 months of therapy (induction arm)
Number of subjects: 106
Study 14709244 — intervention group
Group type: COMPARATOR
Intervention: Ribavirin (RBV) 400 mg bid plus interferon alpha‐2b (IFN‐alpha) 3 mU tiw (control arm)
Number of subjects: 106
Study 11112016 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ATG (9 mg/kg body weight, single intravenous injection)
Number of subjects: 38
Study 11112016 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine-based protocol (control group)
Number of subjects: 38
Study 11112016 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ATG
Number of subjects: 38
Study 9420308 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir
Number of subjects: 0
Study 9420308 — intervention group
Group type: COMPARATOR
Intervention: Nevirapine
Number of subjects: 0
Study 9420308 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine
Number of subjects: 0
Study 9420308 — intervention group
Group type: COMPARATOR
Intervention: RT inhibitors (Nevirapine and Zidovudine)
Number of subjects: 0
Study 8348707 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ampoule of FSH (cycle 1)
Number of subjects: 6
Study 8348707 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ampoules of FSH (cycle 3)
Number of subjects: 6
Study 8348707 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 ampoules of FSH (cycle 6)
Number of subjects: 6
Study 8348707 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cycle P)
Number of subjects: 6
Study 2872811 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin (1 to 40 mg, single daily doses)
Number of subjects: 713
Study 2872811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 713
Study 31125395 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabotegravir
Number of subjects: 0
Study 31125395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29387931 — intervention group
Group type: EXPERIMENTAL
Intervention: Single instillation of THP (30 mg/50 mL) immediately after TURBT (Group A)
Number of subjects: 257
Study 29387931 — intervention group
Group type: COMPARATOR
Intervention: Two-time instillation of THP immediately after and 1 day after TURBT (Group B)
Number of subjects: 257
Study 29387931 — intervention group
Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 257
Study 27643885 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone 20 mg/day
Number of subjects: 199
Study 27643885 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone 40 mg/day
Number of subjects: 199
Study 27643885 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/day
Number of subjects: 199
Study 27643885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 25308780 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel size 1
Number of subjects: 40
Study 25308780 — intervention group
Group type: COMPARATOR
Intervention: cLaryngeal Mask Airway size 1
Number of subjects: 40
Study 23965882 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF1 (mycophenolate mofetil after 2 weeks of conventional treatment)
Number of subjects: 35
Study 23965882 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF2 (combination therapy with non-steroidal anti-inflammatory drugs, prednisone, and MMF)
Number of subjects: 35
Study 23965882 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional treatment)
Number of subjects: 35
Study 21970469 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound-edge protection device
Number of subjects: 750
Study 21970469 — intervention group
Group type: COMPARATOR
Intervention: No wound-edge protection device
Number of subjects: 750
Study 18431048 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine fibroid embolization (UFE)
Number of subjects: 44
Study 16868226 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin (3.6 mg subcutaneously every 4 weeks for 12 weeks)
Number of subjects: 22
Study 16868226 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 22
Study 12182257 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefditoren 200 mg BID for 10 days
Number of subjects: 1685
Study 12182257 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefditoren 400 mg BID for 10 days
Number of subjects: 1685
Study 12182257 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime 250 mg BID for 10 days
Number of subjects: 1685
Study 12182257 — intervention group
Group type: COMPARATOR
Intervention: Cefadroxil 500 mg BID for 10 days
Number of subjects: 1685
Study 12182257 — intervention group
Group type: COMPARATOR
Intervention: Cefditoren 200 mg vs Cefuroxime
Number of subjects: 1685
Study 12182257 — intervention group
Group type: COMPARATOR
Intervention: Cefditoren 200 mg vs Cefadroxil
Number of subjects: 1685
Study 12182257 — intervention group
Group type: COMPARATOR
Intervention: Cefditoren 400 mg vs Cefadroxil
Number of subjects: 1685
Study 12182257 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefditoren 400 mg
Number of subjects: 1685
Study 12182257 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 1685
Study 10482825 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 100 mg daily for 5 months
Number of subjects: 11
Study 10482825 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (continued treatment in phase 2)
Number of subjects: 11
Study 10482825 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 months
Number of subjects: 11
Study 8738765 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily aminoglycoside dosing (ODA)
Number of subjects: 850
Study 1951337 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 8
Study 6783970 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol (9 mosm/kg water)
Number of subjects: 13
Study 6783970 — intervention group
Group type: COMPARATOR
Intervention: 5% glucose in water (control)
Number of subjects: 13
Study 6783970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration rate
Number of subjects: 13
Study 31711969 — intervention group
Group type: EXPERIMENTAL
Intervention: PAINRelieveIt®
Number of subjects: 234
Study 31711969 — intervention group
Group type: COMPARATOR
Intervention: Usual hospice care
Number of subjects: 234
Study 30777094 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine supplementation (GCAF)
Number of subjects: 20
Study 30777094 — intervention group
Group type: COMPARATOR
Intervention: Placebo (GCON)
Number of subjects: 20
Study 27280523 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Psychological Therapy (IPT)
Number of subjects: 48
Study 27280523 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 48
Study 25057140 — intervention group
Group type: EXPERIMENTAL
Intervention: Live Educational Music Therapy
Number of subjects: 96
Study 25057140 — intervention group
Group type: COMPARATOR
Intervention: Recorded Educational Music Therapy
Number of subjects: 96
Study 25057140 — intervention group
Group type: COMPARATOR
Intervention: Recreational Music Therapy
Number of subjects: 96
Study 25057140 — intervention group
Group type: COMPARATOR
Intervention: Education without Music
Number of subjects: 96
Study 25057140 — intervention group
Group type: COMPARATOR
Intervention: Recreational Music Therapy without Education
Number of subjects: 96
Study 22324267 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical audits implemented by the Safe Motherhood Committee
Number of subjects: 3494
Study 22324267 — intervention group
Group type: COMPARATOR
Intervention: Control group (3 other general hospitals without clinical audits)
Number of subjects: 3494
Study 18964302 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab and methimazole for 21 days
Number of subjects: 0
Study 18964302 — intervention group
Group type: COMPARATOR
Intervention: Methimazole alone
Number of subjects: 0
Study 18964302 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab therapy
Number of subjects: 0
Study 18964302 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 0
Study 17219174 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified training (IT) for 6 weeks
Number of subjects: 18
Study 17219174 — intervention group
Group type: COMPARATOR
Intervention: Normal training (NT) for 6 weeks
Number of subjects: 18
Study 17219174 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified training (IT) followed by a 7-day taper
Number of subjects: 18
Study 17219174 — intervention group
Group type: COMPARATOR
Intervention: Normal training (NT) followed by a 7-day taper
Number of subjects: 18
Study 10828848 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) for 6 months
Number of subjects: 81
Study 10828848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 10828848 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 81
Study 9590915 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraligamentary technique of anesthetic administration (ILA)
Number of subjects: 16
Study 9590915 — intervention group
Group type: COMPARATOR
Intervention: Inferior alveolar nerve block (IANB)
Number of subjects: 16
Study 9590915 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 16
Study 8250678 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning light therapy (2500 lux for 1 hour for 1 week)
Number of subjects: 39
Study 8250678 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening light therapy (2500 lux for 1 hour for 1 week)
Number of subjects: 39
Study 2951811 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 40 micrograms ipratropium bromide and 100 micrograms fenoterol (Duovent)
Number of subjects: 20
Study 2951811 — intervention group
Group type: COMPARATOR
Intervention: 250 micrograms terbutaline
Number of subjects: 20
Study 29370572 — intervention group
Group type: EXPERIMENTAL
Intervention: Gevokizumab (60 mg every 4 weeks subcutaneously)
Number of subjects: 83
Study 29370572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 27881152 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy with systematically augmented levels of mobilisation (5 times per week, over 2 weeks; 20 min each session; total of 10 additional sessions)
Number of subjects: 108
Study 27881152 — intervention group
Group type: COMPARATOR
Intervention: In-bed cycling sessions (same number, frequency and treatment time as the intervention group)
Number of subjects: 108
Study 27881152 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy with systematically augmented levels of mobilisation
Number of subjects: 108
Study 27881152 — intervention group
Group type: COMPARATOR
Intervention: In-bed cycling sessions
Number of subjects: 108
Study 24384538 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 0
Study 24384538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22436075 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF-CHO
Number of subjects: 10
Study 22436075 — intervention group
Group type: COMPARATOR
Intervention: CHO
Number of subjects: 10
Study 22436075 — intervention group
Group type: COMPARATOR
Intervention: CAF
Number of subjects: 10
Study 22436075 — intervention group
Group type: COMPARATOR
Intervention: PLA
Number of subjects: 10
Study 20331933 — intervention group
Group type: EXPERIMENTAL
Intervention: MINI‐KID
Number of subjects: 226
Study 20331933 — intervention group
Group type: EXPERIMENTAL
Intervention: MINI‐KID-P
Number of subjects: 226
Study 17987065 — intervention group
Group type: COMPARATOR
Intervention: Dopamine release (DA(rel)) in TS patients
Number of subjects: 14
Study 17987065 — intervention group
Group type: COMPARATOR
Intervention: Dopamine D2 receptor (D2-R) density in TS patients with OCD
Number of subjects: 14
Study 17987065 — intervention group
Group type: COMPARATOR
Intervention: Serotonin transporter binding potential (SERT BP) in TS patients
Number of subjects: 14
Study 17987065 — intervention group
Group type: COMPARATOR
Intervention: Dopamine release (DA(rel)) and serotonin 5-HT2A receptor binding potential (5-HT2A BP) in TS+OCD subjects
Number of subjects: 14
Study 15717937 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding metal stents (SEMS)
Number of subjects: 217
Study 15717937 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-mm SEMS
Number of subjects: 217
Study 15717937 — intervention group
Group type: COMPARATOR
Intervention: Non-stent therapies
Number of subjects: 217
Study 15717937 — intervention group
Group type: COMPARATOR
Intervention: Rigid intubation
Number of subjects: 217
Study 15717937 — intervention group
Group type: COMPARATOR
Intervention: Bipolar electrocoagulation and ethanol tumour necrosis
Number of subjects: 217
Study 15717937 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measures
Number of subjects: 217
Study 15717937 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival measures
Number of subjects: 217
Study 15717937 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-adjusted life-years
Number of subjects: 217
Study 12876113 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief explanation to parents regarding the self-limited nature of AOM and the controversy regarding antibiotic prescription.
Number of subjects: 81
Study 12876113 — intervention group
Group type: COMPARATOR
Intervention: Control group (no brief explanation provided).
Number of subjects: 81
Study 10378599 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented biofeedback
Number of subjects: 40
Study 10378599 — intervention group
Group type: COMPARATOR
Intervention: Sensory biofeedback
Number of subjects: 40
Study 8885916 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral position
Number of subjects: 15
Study 8885916 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 15
Study 8885916 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral position
Number of subjects: 15
Study 2063503 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptogens treatment (0.15 U/kg im insulin, 0.1 mg/kg prednisolone, 0.2 mg/kg dibazol, 250 mg/kg methyluracil daily for 1 week preoperatively)
Number of subjects: 118
Study 2063503 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (0.2 mg/kg intravenous administration)
Number of subjects: 118
Study 31445925 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight catheters
Number of subjects: 308
Study 31445925 — intervention group
Group type: COMPARATOR
Intervention: Coiled catheters
Number of subjects: 308
Study 30225843 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 653
Study 30225843 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 653
Study 30225843 — intervention group
Group type: EXPERIMENTAL
Intervention: De-escalation (switching from ticagrelor to clopidogrel)
Number of subjects: 653
Study 30225843 — intervention group
Group type: COMPARATOR
Intervention: De-escalation, Ticagrelor, Clopidogrel
Number of subjects: 653
Study 26607698 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time (measured using ActiGraph GT3X accelerometer)
Number of subjects: 263
Study 26607698 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time (hours/day)
Number of subjects: 263
Study 25269669 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU vitamin A
Number of subjects: 306
Study 25269669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 22430275 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain of at least 10% of prediagnosis weight
Number of subjects: 3088
Study 22430275 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss of at least 10% of prediagnosis weight
Number of subjects: 3088
Study 22430275 — intervention group
Group type: COMPARATOR
Intervention: Weight stability (within 10% of prediagnosis weight)
Number of subjects: 3088
Study 22430275 — intervention group
Group type: EXPERIMENTAL
Intervention: Trend of weight change (weight loss and weight gain)
Number of subjects: 3088
Study 19996342 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted Abrams needle biopsies
Number of subjects: 89
Study 19996342 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-assisted Tru-Cut needle biopsies
Number of subjects: 89
Study 18511529 — intervention group
Group type: EXPERIMENTAL
Intervention: Group exercise programme run by a physiotherapist (n = 85)
Number of subjects: 173
Study 18511529 — intervention group
Group type: COMPARATOR
Intervention: No-intervention waiting list control group (n = 88)
Number of subjects: 173
Study 15736113 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine (0.1 g/kg)
Number of subjects: 10
Study 15736113 — intervention group
Group type: EXPERIMENTAL
Intervention: Homocysteine (0.01 g/kg)
Number of subjects: 10
Study 15736113 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC) (0.1 g/kg)
Number of subjects: 10
Study 15736113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15736113 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine
Number of subjects: 10
Study 15736113 — intervention group
Group type: EXPERIMENTAL
Intervention: Homocysteine
Number of subjects: 10
Study 15736113 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC)
Number of subjects: 10
Study 15736113 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 10
Study 12952516 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment without deep breathing exercises
Number of subjects: 230
Study 12952516 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy treatment with deep breathing exercises (control)
Number of subjects: 230
Study 11053698 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with acute coronary syndrome (ACS)
Number of subjects: 57
Study 11053698 — intervention group
Group type: COMPARATOR
Intervention: Control patients (neither ACS nor CHF)
Number of subjects: 57
Study 11053698 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with congestive heart failure (CHF)
Number of subjects: 57
Study 8894888 — intervention group
Group type: EXPERIMENTAL
Intervention: Health visitor follow-up intervention; patients seen at home shortly after discharge and screened for new dependency and support needs.
Number of subjects: 414
Study 8894888 — intervention group
Group type: COMPARATOR
Intervention: Control group with no special arrangements made.
Number of subjects: 414
Study 2004365 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexamethylene bisacetamide administered nasogastrically at 12 g/m2/day
Number of subjects: 14
Study 2004365 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexamethylene bisacetamide administered nasogastrically at 24 g/m2/day
Number of subjects: 14
Study 2004365 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexamethylene bisacetamide administered nasogastrically at 30 g/m2/day
Number of subjects: 14
Study 2004365 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexamethylene bisacetamide administered nasogastrically
Number of subjects: 14
Study 2004365 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexamethylene bisacetamide administered nasogastrically or parenterally
Number of subjects: 14
Study 6838743 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position after extradural injection
Number of subjects: 89
Study 6838743 — intervention group
Group type: COMPARATOR
Intervention: Left lateral position throughout
Number of subjects: 89
Study 31217316 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation (VR)
Number of subjects: 183
Study 31217316 — intervention group
Group type: COMPARATOR
Intervention: Betahistine
Number of subjects: 183
Study 31217316 — intervention group
Group type: EXPERIMENTAL
Intervention: VR plus betahistine
Number of subjects: 183
Study 31217316 — intervention group
Group type: EXPERIMENTAL
Intervention: VR
Number of subjects: 183
Study 27514499 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 221
Study 27514499 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline glomerular filtration rate (GFR)
Number of subjects: 221
Study 27514499 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute kidney injury (AKI)
Number of subjects: 221
Study 27514499 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD
Number of subjects: 221
Study 27514499 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic regurgitation grade postprocedure ≥ 2
Number of subjects: 221
Study 26297943 — intervention group
Group type: EXPERIMENTAL
Intervention: Solomon technique
Number of subjects: 287
Study 26297943 — intervention group
Group type: COMPARATOR
Intervention: Standard laser surgery technique
Number of subjects: 287
Study 25483468 — intervention group
Group type: EXPERIMENTAL
Intervention: History of influenza immunization
Number of subjects: 0
Study 25483468 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived susceptibility to influenza during pregnancy
Number of subjects: 0
Study 25483468 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine efficacy
Number of subjects: 0
Study 25483468 — intervention group
Group type: COMPARATOR
Intervention: Single message exposure
Number of subjects: 0
Study 22914552 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (20% of energy derived from fat)
Number of subjects: 734
Study 22914552 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (40% of energy derived from fat)
Number of subjects: 734
Study 19082870 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A (retrospective ECG-gating at 120 kV)
Number of subjects: 100
Study 19082870 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol B (retrospective ECG-gating at 100 kV)
Number of subjects: 100
Study 19082870 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol C (prospective ECG-triggering at 120 kV)
Number of subjects: 100
Study 19082870 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol D (prospective ECG-triggering at 100 kV)
Number of subjects: 100
Study 19082870 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol E (prospective ECG-triggering at 100 kV with attenuation-based tube current modulation)
Number of subjects: 100
Study 19082870 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 100 kV protocols to 120 kV protocols
Number of subjects: 100